With Heterocyclic Compound Patents (Class 514/161)
  • Patent number: 10675275
    Abstract: (1S)-2-acetyl-1-(4-chloro-2-methoxyphenyl)-5-fluoro-1,2,3,9-tetrahydrospiro[?-carboline-4,1?-cyclopropane] can significantly suppress a decrease of a pain threshold compared to well-known TSPO antagonists, and thus can be an excellent prophylactic and/or therapeutic agent for fibromyalgia, fibromyalgia-associated diseases, and fibromyalgia-associated symptoms.
    Type: Grant
    Filed: January 8, 2016
    Date of Patent: June 9, 2020
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Seishi Katsumata, Katsukuni Mitsui, Yuya Ezaki
  • Patent number: 10588898
    Abstract: This application describes compounds that can act as opioid receptor ligands, which compounds can be used in the treatment of, for example, pain and pain related disorders.
    Type: Grant
    Filed: July 25, 2019
    Date of Patent: March 17, 2020
    Assignee: TREVENA, INC.
    Inventors: Dennis Yamashita, Dimitar Gotchev, Philip Pitis, Xiao-Tao Chen, Guodong Liu, Catherine C. K. Yuan
  • Patent number: 10500177
    Abstract: Disclosed herein are methods of preventing, inhibiting, reducing, or treating ischemia and reperfusion injury to tissues with glutarate compounds such as ?-ketoglutarate.
    Type: Grant
    Filed: March 9, 2019
    Date of Patent: December 10, 2019
    Assignee: The Regents of the University of California
    Inventors: Jing Huang, Xudong Fu, Xiang Yin, Mansoureh Eghbali, Jingyuan Li, Karen Reue, Laurent Vergnes
  • Patent number: 10450281
    Abstract: Provided are small molecule inhibitors of ubiquitin specific protease 2, 8 and 12 (USP2 and USP8 and USP12) activity and methods for their use in treating cancers. The small molecule inhibitors of the invention are particularly useful in the treatment of non-small cell lung cancers that are resistant to tyrosine kinase inhibitors and in the treatment of prostate cancer that is resistant to AR inhibitor therapy.
    Type: Grant
    Filed: June 28, 2017
    Date of Patent: October 22, 2019
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Alan D. D'Andrea, Nathanael S. Gray, Sara Jean Buhrlage, Kalindi Parmar
  • Patent number: 10285958
    Abstract: The invention relates to a combination of two or more pharmaceutically active substances, of which at least one is a metabolic product (“metabolite”) of the other (“parent substance”), wherein in particular the dosages thereof are selected such that genotypically or phenotypically related variability in the conversion of the parent substance to the metabolite in particular individuals is compensated for.
    Type: Grant
    Filed: May 27, 2013
    Date of Patent: May 14, 2019
    Assignee: BAYER AKTIENGESELLSCHAFT
    Inventors: Stefan Willmann, Thomas Eiβing, Kristin Dickschen
  • Patent number: 10285962
    Abstract: Disclosed herein are methods of preventing, inhibiting, reducing, or treating ischemia and reperfusion injury to tissues with glutarate compounds such as ?-ketoglutarate.
    Type: Grant
    Filed: April 30, 2017
    Date of Patent: May 14, 2019
    Assignee: The Regents of the University of California
    Inventors: Jing Huang, Xudong Fu, Xiang Yin, Mansoureh Eghbali, Jingyuan Li, Karen Reue, Laurent Vergnes
  • Patent number: 10272155
    Abstract: Methods of enabling or improving the ability of a hydrogel to swell in the stomach of an animal and/or increasing the amount of time said hydrogel remains swollen in the stomach are described herein. In one embodiment, a polymer is administered in combination with one or more pH modifying agents which raise and maintain the pH of the micro environment of the polymer and/or the stomach in order inducing swelling in the polymer. The polymer can be a homopolymer, a copolymer, or a polymer blend or composite. In one embodiment, the polymer is a superabsorbent polymer (“SAP”). The polymers can also be administered with one or more active agents, such as appetite suppressants. The pH modifying agent and/or the active agent can be administered simultaneously with the polymer in the same dosage form, simultaneously with the polymer in separate dosage forms, or sequentially. The compositions are formulated for oral administration.
    Type: Grant
    Filed: January 15, 2015
    Date of Patent: April 30, 2019
    Assignee: Gelesis LLC
    Inventors: Eric Elenko, Eyal S. Ron, Yishai Zohar
  • Patent number: 10220072
    Abstract: Methods of treating renal cancer, including renal cell carcinoma, using mesalamine are disclosed herein. Mesalamine can be administered as a monotherapy or as part of a comprehensive treatment program, which can also include administration with other anti-cancer drugs, surgical treatments or exposure to ionizing radiation.
    Type: Grant
    Filed: December 6, 2017
    Date of Patent: March 5, 2019
    Assignee: Cipla Limited
    Inventors: Geena Malhotra, Kalpana Joshi, Jeevan Ghosalkar
  • Patent number: 10143715
    Abstract: The present invention relates to a pharmaceutical composition or a food supplement composition and use thereof in the prevention and/or treatment of allergy symptoms, preferably allergic rhinitis and/or allergic conjunctivitis symptoms. In particular, the composition according to the invention comprises at least one slow release component comprising quercetin and at least one fast release component comprising an extract from Perilla frutescens or a constituent thereof selected from luteolin, rosmarinic acid, apigenin, catechina, ferulic acid, caffeic acid or mixtures thereof, The invention further comprises the use of the composition in the prevention and/or treatment of allergy symptoms, preferably allergic rhinitis and/or allergic conjunctivitis symptoms.
    Type: Grant
    Filed: September 21, 2015
    Date of Patent: December 4, 2018
    Assignee: NTC S.R.L.
    Inventors: Cesare Busetti, Fabrizio Niccolai, Daniela Zelaschi
  • Patent number: 9993489
    Abstract: Methods for the treatment of solid tumor cancers, specifically ovarian cancer and drug-resistant solid tumors, are disclosed. A method comprises administering a combination therapy including a therapeutically effective amount of an HDAC inhibitor and a therapeutically effective amount of an IKK inhibitor to a subject in need thereof. Pharmaceutical compositions and kits comprising an HDAC inhibitor and an IKK inhibitor are also disclosed.
    Type: Grant
    Filed: January 20, 2017
    Date of Patent: June 12, 2018
    Assignee: St. John's University
    Inventors: Ivana Vancurova, Himavanth R. Gatla, Bipradeb Singha
  • Patent number: 9750727
    Abstract: This invention relates to the field of chemical-pharmaceutical industry, specifically a new tuberculosis treatment that contains, as an active ingredient, 4-thioureido-iminomethylpyridinium perchlorate at a therapeutically effective and safe level and pharmaceutically acceptable excipients. In addition, this treatment relates to a method of the preparation of the new drug, providing a high yield of the new treatment. The new treatment has a higher tuberculostatic activity (200 times as high) and lower toxicity (2.4 times as low), as compared to a prototype drug, and is stable during long-term storage. This medicament may be used for treating and preventing all forms of pulmonary and extrapulmonary TB by using the new treatment in combination with other TB drugs.
    Type: Grant
    Filed: October 22, 2012
    Date of Patent: September 5, 2017
    Assignee: Joint Stock Company “Pharmasyntez”
    Inventors: Aleksander Sergeevich Gushchin, Tatiana Ivanovna Vinogradova, Petr Kazimirovich Yablonskiy, Gennady Andreevich Batyunin, Natalya Vyacheslavovna Zabolotnyh, Svetlana Nikolaevna Vasilieva, Alexey Vladimirovich Maligin
  • Patent number: 9682101
    Abstract: A composition for use in the treatment of a condition or disorder related to mucosal barrier dysfunction in the gut, the composition comprising activated carbon. The condition may be, for example, pouchitis or proctitis.
    Type: Grant
    Filed: March 25, 2014
    Date of Patent: June 20, 2017
    Assignee: FERRING B.V.
    Inventor: Mats Ekelund
  • Patent number: 9675592
    Abstract: Compositions and methods are provided for treating or inhibiting a bacterial infection involving at least one antibiotic and a compound that potentiates the antibiotic activity of the antibiotic. In certain embodiments the antibiotic is a beta lactam. In further embodiments, the antibiotic is oxacillin. In additional embodiments, the potentiating compound is an inhibitor of vraSR operon expression. In specific embodiments, the bacterial infection involves an antibiotic-resistant bacteria.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: June 13, 2017
    Assignees: The University of Chicago, The Board of Regents of the University of Illinois
    Inventors: Robert S. Daum, Susan Boyle-Vavra, Michael E. Johnson
  • Patent number: 9522135
    Abstract: The present invention relates to methods for producing particles of indomethacin using dry milling processes as well as compositions comprising indomethacin, medicaments produced using indomethacin in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of indomethacin administered by way of said medicaments.
    Type: Grant
    Filed: July 27, 2015
    Date of Patent: December 20, 2016
    Assignee: iCeutica Pty Ltd.
    Inventors: Aaron Dodd, Felix Meiser, Marck Norret, Adrian Russell, H. William Bosch
  • Patent number: 9089471
    Abstract: The present invention relates to methods for producing particles of indomethacin using dry milling processes as well as compositions comprising indomethacin, medicaments produced using indomethacin in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of indomethacin administered by way of said medicaments.
    Type: Grant
    Filed: May 22, 2014
    Date of Patent: July 28, 2015
    Assignee: iCeutica Pty Ltd.
    Inventors: Aaron Dodd, Felix Meiser, Marck Norret, Adrian Russell, H. William Bosch
  • Publication number: 20150148319
    Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.
    Type: Application
    Filed: January 30, 2015
    Publication date: May 28, 2015
    Applicants: PURDUE PHARMACEUTICALS L.P., THE P.F. LABORATORIES, INC.
    Inventors: Curtis Wright, Benjamin Oshlack, Christopher Breder
  • Publication number: 20150125541
    Abstract: In a gel-like mass having natural or synthetic polymers, preferably polygalactomannans, at least one cross-linking agent and further ingredients, according to this invention that the at least one cross-linking agent is of amphiphilic core-shell nanoparticles. This invention further refers to a method for producing a gel-like mass, a composition for producing a gel-like mass comprising natural or synthetic polymers, preferably polygalactomannans and amphiphilic core-shell nanoparticles and the use of a gel-like mass as drug delivery system for topical medication.
    Type: Application
    Filed: April 18, 2013
    Publication date: May 7, 2015
    Inventors: Meinrad Flury, Benjamin Tak Kwong Lee, Pei Li, Edmond Ho Kin Man
  • Publication number: 20150126479
    Abstract: What is described herein is an environment-friendly, highly aqueous solution of 1,2-benzisothiazolin-3-one (BIT) which is free from volatile organic compounds (VOC's), glycols, derivatives of glycols, glycerols and/or derivatives of glycerols. The composition comprises: (i) about 0.1% to about 30% by wt. of BIT; (ii) about 5% to about 15% by wt. of neutralizing agent; (iii) about 50% to about 85% by wt. of water; and (iv) about 0.1% to about 5% by wt. of chelating agent. The aqueous solution of BIT may further comprise at least one water soluble form of a co-biocide. The composition is efficient in protecting aqueous media against microbial attack in various industrial applications.
    Type: Application
    Filed: May 9, 2012
    Publication date: May 7, 2015
    Applicant: ISP Investments Inc.
    Inventors: Raman Premachandran, Karen Winkowski, Najeeb H. Hakimi
  • Publication number: 20150118229
    Abstract: The invention relates to the use of a JAK1 kinase-selective inhibitor that has minimal inhibitory activity towards Jak2 kinase for treating a disease, such as an inflammatory disease (e.g., moderate to severe Rheumatoid Arthritis) and/or bone loss, either alone or in combination with a DMARD (disease modifying anti-rheumatic drug), such as methotrexate. The invention also provides pharmaceutical composition, dosage formulation, administration route, and dosage schedule thereof.
    Type: Application
    Filed: October 24, 2014
    Publication date: April 30, 2015
    Applicant: ABBVIE INC.
    Inventors: Jeffrey W. Voss, Heidi S. Camp, Robert J. Padley
  • Publication number: 20150111730
    Abstract: A pesticidal composition comprises a compound of formula I or any agriculturally acceptable salt thereof, wherein R1, R2, R4, R5, R6, R7, Z, Q, and Y are as described herein. A method of controlling pests comprises applying the pesticidal composition near a population of pests, or to an area to control pests.
    Type: Application
    Filed: October 17, 2014
    Publication date: April 23, 2015
    Inventors: Noormohamed M. Niyaz, Ann M. Buysse, David A. Demeter, Negar Garizi, Ricky Hunter, Daniel Knueppel, Paul R. LePlae, Christian T. Lowe, Akshay Patny, Tony K. Trullinger, Martin J. Walsh, Yu Zhang
  • Publication number: 20150105356
    Abstract: The subject invention pertains to materials and methods for the prevention and treatment of disease conditions associated with oxidative stress or a compromised reducing environment, including inflammatory bowel diseases such as Crohn's disease and ulcerative colitis. Another aspect of the subject invention concerns compositions formulated for administration as an enema. In one embodiment, a composition suitable for administration as an enema comprises an effective amount of 5-ASA and a steroid such as budesonide or hydrocortisone. The subject invention also concerns compositions formulated for oral administration. In one embodiment, a composition comprises alpha-lipoic acid, and/or N-acetyl-L-cysteine (N-A-C), and/or L-glutamine. The alpha-lipoic acid can be racemic alpha-lipoic acid, R-lipoic acid, or R-dihydro-lipoic acid. Methods of the invention include administration of compounds or compositions of the invention.
    Type: Application
    Filed: December 22, 2014
    Publication date: April 16, 2015
    Applicant: THERAPEUTIC RESEARCH LLC
    Inventor: Jay Pravda
  • Publication number: 20150094285
    Abstract: A composition (e.g., phytochemical composition) including sesamin, the composition exhibiting anti-inflammatory, anti-cytokine storm, connective tissue preservation, anti-viral, and/or other properties in biological tissue. The phytochemical composition therapeutically affects a pro-inflammatory cytokine condition, for instance facilitating or effectuating decrease in a quantity of a pro-inflammatory cytokine, for example, interleukin-1 and tumor necrosis-alpha. The phytochemical composition facilitates or effectuates an increase in quantity of an anti-inflammatory cytokines. The phytochemical composition can additionally facilitate a connective tissue extracellular matrix (ECM) preservation effect. The phytochemical composition can also inhibit an action of a viral neuraminidase, for example, the influenza A virus neuraminidase.
    Type: Application
    Filed: December 5, 2014
    Publication date: April 2, 2015
    Applicants: COMMISSION ON HIGHER EDUCATION, CHIANG MAI UNIVERSITY
    Inventor: Prachya KONGTAWELERT
  • Publication number: 20150079169
    Abstract: The present invention provides for novel formulations of clopidogrel in combination with proton pump inhibitors (PPI) and optionally with NSAIDs, for use as improved antiplatelet therapies in stroke and cardiovascular indications. The invention provides the delivery of clopidogrel in pulses or waves, such that the total dose is phased/spread out over time and, advantageously, combined with omeprazole in a way to minimize the conflicting actions these two drugs may have on each other. In addition, the invention also provides the delivery of clopidogrel and a PPI, and optionally aspirin, in a sequential (orderly) manner that would allow for the delivery and metabolism of clopidogrel first, followed by the PPI, and thereafter optionally aspirin. A particular mode of the invention involves the combination of clopidogrel with coformulated immediate release omeprazole+enteric coated aspirin.
    Type: Application
    Filed: September 14, 2012
    Publication date: March 19, 2015
    Applicant: POZEN INC.
    Inventor: John R. Plachetka
  • Publication number: 20150072005
    Abstract: Provided are methods for enhancing the efficacy of aspirin. Also provided are methods for reducing pain or preventing or treating heart attack, stroke or blood clot in a subject in need thereof. The methods entail orally administering to the subject a first composition comprising a first amount of aspirin, and a second composition comprising a second amount of aspirin, wherein the first composition is formulated so as to, upon administration, disintegrate or dissolve intraorally providing rapid release of the aspirin of the first composition in the subject, and wherein the second composition is formulated to be substantially more difficult than the first composition to disintegrate or dissolve intraorally but is ingestible and releasable in the gastrointestinal track of the subject. The method can further include administering to the subject a painkiller or an agent suitable for treating a cardiovascular disease or condition.
    Type: Application
    Filed: September 10, 2013
    Publication date: March 12, 2015
    Inventor: Joseph P. Habboushe
  • Publication number: 20150071992
    Abstract: A concentrated inhalable formulation of an antibiotic drug such as ciprofloxacin is disclosed. The antibiotic is formulated with sodium acetate and liposome which incorporate antibiotic. The formulation is aerosolized and inhaled for treatment of respiratory tract infections and other medical conditions.
    Type: Application
    Filed: November 25, 2014
    Publication date: March 12, 2015
    Inventors: DAVID C. CIPOLLA, JAMES BLANCHARD
  • Patent number: 8962574
    Abstract: A method for preventing stroke in a patient suffering from atrial fibrillation, wherein the patient has at least one risk factor for major bleeding events, the method comprising administering to the patient 110 mg b.i.d. of dabigatran etexilate, optionally in the form of a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: November 10, 2009
    Date of Patent: February 24, 2015
    Assignee: Boehringer Ingelheim International GmbH
    Inventor: Paul Anthony Reilly
  • Publication number: 20150050342
    Abstract: Compositions are provided comprising: (i) chlorhexidine or a pharmaceutically acceptable salt thereof; (ii) niacinamide or niacin; and (iii) salicylic acid or a pharmaceutically acceptable salt or derivative thereof. The compositions are suitable for use in treating and preventing disorders of the skin. The compositions are also provided in the form of cosmetic products.
    Type: Application
    Filed: July 20, 2012
    Publication date: February 19, 2015
    Inventors: Nicholas Lowe, Philippa Lowe
  • Publication number: 20150045332
    Abstract: The present invention relates to sphingosine-1-phosphate (S1P) receptors and compounds of the general formula: that are useful in the treatment and prevention of conditions associated with such receptors. More specifically, the present invention relates to the synthesis and use of sphingosine 1-phosphate receptor 2 (S1P2) antagonists that are useful in the treatment of cancer, atherosclerosis, diabetic retinopathy, and other inflammatory diseases. Among these inflammatory diseases that could be treated with these S1P2 antagonist are those characterized by fibrosis including chronic lung disease, chronic kidney and liver disease, chronic heart disease, and skin diseases such as sclerosis/scleroderma. The S1P2 antagonists can also be used in the treatment of glioblastoma multiforme (brain cancer), pediatric neuroblastoma, and other cancers.
    Type: Application
    Filed: March 21, 2013
    Publication date: February 12, 2015
    Inventor: Rolf E. SWENSON
  • Publication number: 20150037318
    Abstract: This invention provides a method of treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome comprising administering to the subject laquinimod as an add-on therapy to or in combination with flupirtine. This invention also provides a package and a pharmaceutical composition comprising laquinimod and flupirtine for treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention also provides laquinimod for use as an add-on therapy or in combination with flupirtine in treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention further provides use of laquinimod and flupirtine in the preparation of a combination for treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome.
    Type: Application
    Filed: July 30, 2014
    Publication date: February 5, 2015
    Applicant: TEVA PHARMACEUTICAL INDUSTRIES, LTD.
    Inventors: David Silver, Einat Amit Romach
  • Patent number: 8946451
    Abstract: The invention relates to lipoic acid acylated salicylate derivatives; compositions comprising an effective amount of a lipoic acid acylated salicylate derivative; and methods for treating or preventing an metabolic disease comprising the administration of an effective amount of a lipoic acid acylated salicylate derivative.
    Type: Grant
    Filed: October 5, 2010
    Date of Patent: February 3, 2015
    Assignee: Catabasis Pharmaceuticals, Inc.
    Inventors: Jill C. Milne, Michael R. Jirousek, Jean E. Bemis, Chi B. Vu
  • Patent number: 8940751
    Abstract: The present disclosure relates to purine compounds of formula (I) or formula (II) or its tautomers, polymorphs, stereoisomers, solvates or a pharmaceutically acceptable salts, or pharmaceutical compositions containing them and methods of treating conditions and diseases that are mediated by thereof as A2B adenosine receptor antagonists. The compounds of the present disclosure are useful in the treatment, prevention or suppression of diseases and disorders that may be susceptible to improvement by the mediation of adenosine A2B receptor. The present disclosure also relates to methods for the preparation of such compounds, and to pharmaceutical compositions containing them.
    Type: Grant
    Filed: September 9, 2011
    Date of Patent: January 27, 2015
    Assignee: Advinus Therapeutics Private Limited
    Inventors: Dinesh Barawkar, Sujay Basu, Vidya Ramdas, Venkata Poornapragnacharyulu Palle, Yogesh Waman, Meena Patel, Anil Panmand
  • Publication number: 20150025046
    Abstract: The present invention relates to bicyclic himbacine derivatives of the formula or a pharmaceutically acceptable salt thereof, wherein: X is —O—, —N(R), —C(R8)(R9) or —C(O)—; and Y is —O—, —N(R), —C(R8)(R9) or —C(O)— and the remaining variables are described herein. The compounds of the invention are effective inhibitors of the PAR-1 receptor. The inventive compounds may be used for the treatment or prophylaxis of disease states such as ACS, secondary prevention of myocardial infarction or stroke, or PAD.
    Type: Application
    Filed: February 27, 2013
    Publication date: January 22, 2015
    Inventors: Mihir Mandal, Timothy A. Blizzard, Helen Chen, Harry Chobanian, Yan Guo, Barbara Pio, Zhicai Wu, Tesfaye Biftu, William J. Greenlee, Johnny Zhaoning Zhu
  • Publication number: 20150024042
    Abstract: The present invention provides for novel formulations of clopidogrel to provide for phased/spaced release for use as improved antiplatelet therapies in stroke and cardiovascular indications.
    Type: Application
    Filed: September 14, 2012
    Publication date: January 22, 2015
    Applicant: POZEN INC.
    Inventor: John R. Plachetka
  • Publication number: 20150017267
    Abstract: The present invention relates to the prevention, reduction, inhibition and reversal of pain and inflammation in a non-human mammal by administration of an inhibitor of soluble epoxide hydrolase, as sole active agent or co-administered with other active agents.
    Type: Application
    Filed: March 5, 2013
    Publication date: January 15, 2015
    Applicant: The Regents of the University of California
    Inventors: Alonso G.P. Guedes, Bruce D. Hammock, Christophe Morisseau
  • Publication number: 20150004216
    Abstract: A medicant composition is provided. The composition includes a film layer and a powder matrix layer. The powder matrix layer includes a medicant. The powder matrix layer is applied to the film layer by admixing particulate to form a powder matrix and by then applying the powder matrix to the film layer by any desired method. The composition of the powder matrix is varied to alter the dissolution rate of the medicant, the adhesion of the medicant composition, and other physical properties of the powder matrix. The powder matrix layer can be cured.
    Type: Application
    Filed: September 19, 2014
    Publication date: January 1, 2015
    Inventor: Robert Steven Davidson
  • Publication number: 20140377247
    Abstract: Novel benzamide compounds including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa are described. Compositions containing such compounds are also described. The compounds and compositions are useful in vitro or in vivo for preventing or treating coagulation disorders.
    Type: Application
    Filed: February 7, 2014
    Publication date: December 25, 2014
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Bing-Yan ZHU, Penglie ZHANG, Lingyan WANG, Wenrong HUANG, Erick A. GOLDMAN, Wenhao LI, Jingmei ZUCKETT, Yonghong SONG, Robert M. SCARBOROUGH
  • Publication number: 20140370088
    Abstract: The present disclosure is directed to a method for delivering a pharmaceutical composition to a patient in need thereof, comprising: administering to said patient a pharmaceutical composition in unit dose form comprising acetylsalicylic acid, or pharmaceutically acceptable salt thereof, and omeprazole, or pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: December 27, 2012
    Publication date: December 18, 2014
    Applicant: POZEN INC.
    Inventor: John R. Plachetka
  • Patent number: 8901111
    Abstract: Certain aryl-substituted heterocyclic urea compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, energy metabolism disorders, and movement disorders (e.g., multiple sclerosis).
    Type: Grant
    Filed: June 4, 2010
    Date of Patent: December 2, 2014
    Assignee: Janssen Pharmaceutica NV
    Inventors: J. Guy Breitenbucher, Mark S. Tichenor, Jeffrey E. Merit, Natalie A. Hawryluk, Alison L. Chambers, John M. Keith
  • Patent number: 8900565
    Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of histone deacetylase 8 (HDAC8). Also described herein are methods of using such HDAC8 inhibitors, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of HDAC8 activity.
    Type: Grant
    Filed: November 21, 2012
    Date of Patent: December 2, 2014
    Assignee: Pharmacyclics, Inc.
    Inventors: Joseph J. Buggy, Sriram Balasubramanian, Erik Verner, Vincent W. F. Tai, Chang-Sun Lee
  • Publication number: 20140348957
    Abstract: The present invention is a compound comprising an NSAID portion and at least one of a progestin portion and a progesterone portion. The compound may take for instance the form of a pill or pellet (for oral internal use or for subdermal implantation), an injectable solution, or a suppository. The compound is intended for use in treating subjects having or being at increased risk—especially genetically determined risk—of developing endometriosis. The compound may also be used for treating other disorders or as a contraceptive.
    Type: Application
    Filed: May 19, 2014
    Publication date: November 27, 2014
    Inventor: Bradley C. Robinson
  • Publication number: 20140341988
    Abstract: Pharmaceutical dosage forms, particularly dosage forms in granular form having good palatability and capable of rapidly and completely dispersed in the mouth when orally administered.
    Type: Application
    Filed: May 15, 2014
    Publication date: November 20, 2014
    Applicant: APR APPLIED PHARMA RESEARCH SA
    Inventors: Alberto REINER, Giorgio REINER
  • Patent number: 8889659
    Abstract: The present invention relates to TRPV1 selective agonist topical compositions including capsaicinoid and analgesic agent compositions and methods of manufacture and methods of providing pain relief as well as treating a variety of disorders with such compositions.
    Type: Grant
    Filed: September 10, 2012
    Date of Patent: November 18, 2014
    Assignee: API Genesis, LLC
    Inventors: Daniel Bucks, Philip J. Birbara
  • Patent number: 8889902
    Abstract: Novel betaine salts of acetylsalicylic acid, namely 4-trimethylammoniobutanoate acetylsalicylic acid addition salt (gamma-butyrobetaine acetylsalicylate), L-carnitine acetylsalicylic acid addition salt and 3-(trimethylammonioamino)propanoate (meldonium) acetylsalicylic acid addition salt. Use of meldonium acetylsalicylate as antiplatelet agent for treating various pathologies induced by platelet aggregation, anti-inflammatory and antihyperlipidemic agent.
    Type: Grant
    Filed: June 21, 2010
    Date of Patent: November 18, 2014
    Assignee: Tetra, SIA
    Inventors: Ivars Kalvins, Anatolijs Birmans, Maris Veveris, Antons Lebedevs, Anatolijs Misnovs
  • Publication number: 20140335181
    Abstract: Provided is a dry coated tablet showing high stability of the active ingredient (proton pump inhibitor, acetylsalicylic acid), which stably and rapidly expresses the pharmacological effect of the active ingredient after administration. A dry coated tablet having an inner core and an outer layer, wherein the inner core is an enteric-coated tablet containing acetylsalicylic acid, and the outer layer contains enteric micro granules containing a proton pump inhibitor.
    Type: Application
    Filed: November 29, 2012
    Publication date: November 13, 2014
    Inventors: Tetsuya Kawano, Yasushi Mima, Yumiko Ishii
  • Patent number: 8883767
    Abstract: A low ether gel composition for application to skin comprising a keratolytic agent, in particular salicylic acid, and comprising a nitrocellulose and one or more volatile ingredients, which forms a film on contact with skin adequate to form a protective barrier for the keratolytic agent for a period of time necessary to provide treatment to the skin; methods of treating using such compositions, and dispensers containing such compositions.
    Type: Grant
    Filed: October 4, 2010
    Date of Patent: November 11, 2014
    Assignee: MSD Consumer Care, Inc.
    Inventors: Gerald R. Dever, Eric Chen-nan Su, William Scott Rogersr, Robert C. Johnson
  • Publication number: 20140329781
    Abstract: The present invention relates to a once-a-day therapeutically synergistic pharmaceutical dosage form for treatment of cardiovascular disorders, wherein the dosage form comprises a fixed dose combination of metoprolol in extended release form and one or more antiplatelet agent along with one or more rate controlling excipients.
    Type: Application
    Filed: November 1, 2012
    Publication date: November 6, 2014
    Applicant: WOCKHARDT LIMITED
    Inventors: Mandar Kodgule, Amit Gupta, Premchand Nakhat, Girish Kumar Jain
  • Publication number: 20140328775
    Abstract: A cosmetic composition suitable for topical application, for example, is provided. In some examples, the cosmetic composition may include batyl alcohol, undecylenoyl phenylalanine, hexyldecanol, and bisabolol. A method of reducing the synthesis of melanin by using the cosmetic compositions is also disclosed herein.
    Type: Application
    Filed: May 1, 2014
    Publication date: November 6, 2014
    Applicant: The Procter & Gamble Company
    Inventors: Leo Timothy LAUGHLIN, II, Tomohiro HAKOZAKI, Shuhei TANAKA
  • Publication number: 20140303074
    Abstract: The present disclosure provides methods of reducing immunodeficiency virus transcription, involving use of diflunisal or an active ester thereof. The disclosure also provides methods of treating an immunodeficiency virus infection in an individual, the method generally involving administering to the individual an effective amount of diflunisal or an active ester thereof.
    Type: Application
    Filed: December 12, 2012
    Publication date: October 9, 2014
    Inventors: Eric M. Verdin, Kotaro Shirakawa
  • Publication number: 20140288028
    Abstract: The present invention provides for salts comprising a compound of Formula I and an acid that has activity against mammalian factor Xa. The present invention is also directed to methods of making the compound of Formula I.
    Type: Application
    Filed: February 17, 2014
    Publication date: September 25, 2014
    Inventors: Craig Grant, James P. Kanter, Graeme Langlands
  • Publication number: 20140271921
    Abstract: A topical composition comprises at least 5 wt % metronidazole or a pharmacologically acceptable derivative thereof in a non-aqueous vehicle. The composition may be used in the treatment of conditions of the colon, rectum, anorectum and perianal region, in particular inflammatory bowel disease and perianal Crohn's disease. The composition also relieves pain and inflammation and promotes healing of the colon, rectum, anorectum and perianal region following surgical operations. One advantage of the composition is that topical administration of metronidazole results in a primarily local effect and thus side effects observed from systemic administration are avoided.
    Type: Application
    Filed: May 28, 2014
    Publication date: September 18, 2014
    Applicant: SLA PHARMA AG
    Inventor: DAVID NIGEL ARMSTRONG